All News

Data from an updated systematic literature review show positive outcomes for both cervical and non-cervical disease in men and women.

Australia also experienced their highest flu season in 5 years, which may foreshadow a bad flu season in the Northern Hemisphere.

Our Best Shot (OBS) is a new children’s book explaining why we should get an annual flu shot and it is not something to fear…and adults may even benefit, said the author.

Students should prepare to be preceptors early in their pharmacy school careers.

Researchers also noted an increasing rate of seroconversion with COVID-19 booster vaccination series.

Melanie Galvin, PharmD, BCSCP, explains how Northwell Health implemented changes to bring the health system up-to-date with the revisions to USP chapters <797> and <800>.

Findings support the potential protective association of vaccination in reducing long COVID, although it does not appear to eliminate the risk.

Reemergence of pertussis continues despite high immunization rates.

Children's books about the field of pharmacy are surprisingly scarce.

Approximately 2 years after patients were infected with COVID-19, non-hospitalized patients suffered from post-COVID-19 symptoms nearly 8% more than hospitalized patients.

Research also focuses on connection between oral hygiene and other chronic diseases, neurological disorders, pulmonary infections.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

The seasonal flu vaccine should be prioritized for those with SCN1A-positive Dravet syndrome, because of the likelihood of severe neurological symptoms and complications.

Although long-term health issues from COVID-19 are a major public health concern, evidence on post-acute COVID-19 syndrome, or post-COVID-19, is still limited, specifically among children and adolescents.

Mild preeclampsia and late-developing preeclampsia were not found to increase risk of stroke as much as early-stage.

The objective of the study was to estimate recent trends in cigarette use and health insurance coverage for US adults with and without mental health and SUD.

Demand for treatment of anxiety and depression remained high for the third consecutive year as the demand for the treatment of trauma- and stressor-related and substance use disorders has increased.

Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.

New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.

Both of Moderna's bivalent boosters showed neutralizing activity against BQ.1.1, an increasingly dominant emerging variant, confirming that updated vaccines have the potential to offer protection as the virus continues to evolve.

Annie Lambert, PharmD, BCSCP, discusses how to approach the implementation of the revised USP chapter guidelines before the enforcement date in fall 2023.

Analysis shows that the therapy is associated with a reduced acute toxicity burden associated with intensity-modulated radiation therapy.

Teplizumab-mzwv is administered through injection and can delay the onset of type 1 diabetes in adults and pediatric patients.

Brian Serumaga, PhD, of US Pharmacopeia (USP) discusses the revisions to compounding chapters <795> and <797> and the resources available to help pharmacists update their practices.

Education and support inspire trust between patients and pharmacists.

A compliance officer role represents an exciting new challenge to ensure safe handling in compliance with United States Pharmacopeia.

Bepirovirsen produced sustained clearance of hepatitis B virus and hepatitis B surface antigens.

Dapagliflozin is the first SGLT2 inhibitor approved by the FDA for treatment of patients with heart failure (NYHA class II-IV) with reduced ejection fraction.

Patients administered 75 mg or higher of olpasiran every 12 weeks had a 95% or greater reduction in Lp(a) compared to placebo at week 36.

The Elecsys NT-proBNP test is an objective biomarker that aids in the diagnosis of individuals believed to have congestive heart failure.